Theviridoside is primarily investigated for its potential antiviral properties, particularly against certain enveloped viruses. It has shown inhibitory effects in early-stage viral entry by interfering with viral fusion to host cell membranes. This makes it a candidate for development in antiviral therapeutics, especially for viruses that rely on membrane fusion for infection. Additionally, Theviridoside exhibits anti-inflammatory activity by modulating cytokine production, which may be beneficial in managing inflammatory responses associated with viral infections. Due to its natural origin and low cytotoxicity in preliminary studies, it is also being explored as a lead compound for designing derivatives with enhanced bioavailability and potency. Research is ongoing in preclinical models to evaluate its efficacy and safety profile for potential pharmaceutical use.